Intervention not reported
Adverse events · participants with CTEV (type of case (i.e. whether initial presentation or relapsed) not specified)
1 finding from 1 review
- no estimate extracted1 study · 5 participantsLow
Findings
What do systematic reviews say?
424 questions · 424 findings · 136 reviews
No studies found 93 · 21.9%GRADE not reported 14 · 3.3%Very low 130 · 30.7%Low 114 · 26.9%Moderate 58 · 13.7%High 15 · 3.5%
Intervention not reported
Adverse events · participants with CTEV at initial presentation
The intervention may leads to lower adverse events (low certainty).
1 finding from 1 review
- no estimate extracted1 study · 25 participantsLow
5‐ASA vs placebo
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.07 [0.6, 1.91]4 studies · 466 participantsLow
High dose 5‐ASA vs low dose 5‐ASA
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.04 [0.15, 7.24]1 study · 206 participantsLow
5‐ASA vs purine antimetabolites
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.11 [0.97, 1.27]5 studies · 425 participantsLow
5‐ASA vs anti TNF‐ɑ
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.13 [0.75, 1.71]1 study · 34 participantsVery low
Sulphasalazine vs placebo
Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
5‐ASA vs no treatment
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 5 [0.25, 101.81]110 participantsVery low
Intervention not reported
Adverse events · patients with antipsychotic‐induced TD
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
- Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes onlyRR 4.549 studies · 284 participantsVery low
Chlormethiazole vs placebo
Adverse events · people with acute stroke
Chlormethiazole probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Gamma aminobutyric acid (GABA) receptor agonists for acute stroke 2018 · Cochrane Headline outcomes onlyRR 4.56 [3.5, 5.95]2 studies · 2527 participantsModerate
Diazepam vs placebo
Adverse events · people with acute stroke
Diazepam showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Gamma aminobutyric acid (GABA) receptor agonists for acute stroke 2018 · Cochrane Headline outcomes onlyRR 0.99 [0.75, 1.31]1 study · 865 participantsModerate
Intervention not reported
Adverse events · people with ALS/MND
1 finding from 1 review
- Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes onlyno estimate extracted2 studies · 353 participantsHigh
Intervention not reported
Adverse events · people with cancer pain
1 finding from 1 review
- no estimate extracted2 studies · 80 participantsVery low
5‐ASA vs placebo
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn's disease 2016 · Cochrane Headline outcomes onlyRR 1.05 [0.95, 1.17]10 studies · 1814 participantsLow
Intervention not reported
Adverse events · patients with chronic hepatitis C
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- RR 0.98 [0.84, 1.14]35 studies · 5646 participantsModerate
Intervention not reported
Adverse events · patients with chronic hepatitis C.
It is very uncertain whether the intervention changes adverse events (very low certainty).
1 finding from 1 review
- Aminoadamantanes versus other antiviral drugs for chronic hepatitis C 2014 · Cochrane Headline outcomes onlyRR 0.56 [0.27, 1.16]4 studies · 427 participantsVery low
Combined paracetamol plus ibuprofen in a single tablet (e.g. paracetamol 1000 mg/ibuprofen 400 mg or 500/200 mg) vs Single drugs given separately (paracetamol 1000 mg or ibuprofen 400 mg)
Adverse events · Patients with pain after surgical removal of lower wisdom teeth (third molars) requiring bone removal or with baseline moderate to severe…
1 finding from 1 review
- Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth 2013 · Cochrane All outcomesStudy period (immediate postoperative)The majority of adverse events were minor in nature and usually included nausea, vomiting, headaches and dizziness. Side effect profiles have not been included in a meta-analysis as multiple adverse events were…2 studiesGRADE not reported
TACE followed by 3‐DCRT vs chemoembolisation
Non‐serious adverse events: serum transaminases elevation · primary hepatocellular carcinoma
It is very uncertain whether TACE followed by 3‐DCRT changes non‐serious adverse events: serum transaminases elevation compared with TACE (very low certainty).
1 finding from 1 review
- Transcatheter arterial chemoembolisation followed by three‐dimensional conformal radiotherapy versus transcatheter… 2019 · Cochrane Headline outcomes onlyRR 1.67 [0.66, 4.27]4 studies · 280 participantsVery low
Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 compared with interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) (moderate certainty).
1 finding from 1 review
- RR 1.75 [1.43, 2.16]1 study · 735 participantsModerate
Adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver transplantation vs liver transplantation
Adverse events considered non‐serious · participants with unresectable hepatocellular carcinoma
It is very uncertain whether adenovirus‐thymidine kinase with ganciclovir (ADV‐TK/GCV) plus liver… changes adverse events considered non‐serious (number of participants) compared with liver transplantation (very low certainty).
1 finding from 1 review
- RR 20.13 [1.25, 324]1 study · 45 participantsVery low